Millennium Management
PRLD icon

Millennium Management’s Prelude Therapeutics PRLD Stock Holding History

Millennium Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31M Buy
382,737
+231,740
+153% +$608K ﹤0.01% 4182
2025
Q4 		$438K Sell
150,997
-996,047
-87% -$1.68M ﹤0.01% 5033
2025
Q3 		$1.65M Buy
1,147,044
+898,621
+362% +$901K ﹤0.01% 4221
2025
Q2 		$201K Buy
248,423
+101,653
+69% +$88K ﹤0.01% 5360
2025
Q1 		$113K Sell
146,770
-315,785
-68% -$295K ﹤0.01% 5419
2024
Q4 		$590K Buy
462,555
+302,031
+188% +$401K ﹤0.01% 4616
2024
Q3 		$332K Buy
+160,524
New +$743K ﹤0.01% 5131
2024
Q2 		– Sell
-101,850
Closed -$483K – 6391
2024
Q1 		$483K Buy
101,850
+4,884
+5% +$19K ﹤0.01% 4849
2023
Q4 		$414K Buy
96,966
+33,099
+52% +$101K ﹤0.01% 4759
2023
Q3 		$197K Sell
63,867
-74,626
-54% -$280K ﹤0.01% 5131
2023
Q2 		$623K Buy
138,493
+1,974
+1% +$11.8K ﹤0.01% 4389
2023
Q1 		$778K Buy
136,519
+86,783
+174% +$529K ﹤0.01% 4311
2022
Q4 		$300K Sell
49,736
-10,690
-18% -$68.5K ﹤0.01% 5113
2022
Q3 		$399K Sell
60,426
-30,511
-34% -$206K ﹤0.01% 5137
2022
Q2 		$475K Buy
90,937
+51,626
+131% +$263K ﹤0.01% 4992
2022
Q1 		$271K Sell
39,311
-404,800
-91% -$3.7M ﹤0.01% 5629
2021
Q4 		$5.53M Buy
444,111
+403,260
+987% +$6.56M ﹤0.01% 2798
2021
Q3 		$1.28M Buy
40,851
+19,893
+95% +$644K ﹤0.01% 4416
2021
Q2 		$600K Buy
20,958
+7,455
+55% +$265K ﹤0.01% 5141
2021
Q1 		$585K Buy
+13,503
New +$896K ﹤0.01% 4693
2020
Q4 		– Sell
-189,573
Closed -$5.71K – 5509
2020
Q3 		$5.71K Buy
+189,573
New +$5.35M 0.01% 1720

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management's PRLD Position: Q1 2026 in Review

Millennium Management increased its Prelude Therapeutics (PRLD) stake by 153% in Q1 2026, buying an estimated $608K and bringing the position to 382,737 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #4182.

Millennium Management first reported a position in PRLD in Q3 2020 and has held it in 21 quarters since. The position peaked at $5.53M in Q4 2021. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Millennium Management held 382,737 shares of Prelude Therapeutics worth $1.31M as of Q1 2026.
  • Millennium Management bought 231,740 Prelude Therapeutics shares in Q1 2026, an estimated $608K.
  • Prelude Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4182 holding.
  • Millennium Management first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Millennium Management's Prelude Therapeutics position peaked at $5.53M in Q4 2021.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.